Polar Capital Holdings’s Blueprint Medicines BPMC Stock Holding History

Polar Capital Holdings’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-541,379	Closed	-$47.9M	–	276
2025 Q1	$47.9M	Sell	541,379 -85,000	-14%	-$8.29M	0.29%	97
2024 Q4	$54.6M	Sell	626,379 -250,626	-29%	-$23M	0.31%	86
2024 Q3	$81.1M	Buy	877,005 +2,005	+0.2%	+$199K	0.39%	59
2024 Q2	$94.3M	Buy	875,000 +10,000	+1%	+$1M	0.56%	49
2024 Q1	$82.1M	Hold	865,000	–	–	0.43%	61
2023 Q4	$79.8M	Sell	865,000 -175,000	-17%	-$11.3M	0.49%	56
2023 Q3	$52.2M	Buy	1,040,000 +540,000	+108%	+$28.9M	0.39%	75
2023 Q2	$31.6M	Buy	+500,000	New	+$27.2M	0.16%	117
2022 Q1	–	Sell	-250,000	Closed	-$26.8K	–	463
2021 Q4	$26.8K	Buy	250,000 +150,000	+150%	+$15.7M	0.1%	146
2021 Q3	$10.3K	Buy	+100,000	New	+$9.31M	0.04%	229

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Polar Capital Holdings's BPMC Position: Q2 2025 in Review

Polar Capital Holdings sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 541,379 shares — an estimated $47.9M sold.

Polar Capital Holdings first reported a position in BPMC in Q3 2021 and held it in 10 quarters. The position peaked at $94.3M in Q2 2024. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Polar Capital Holdings reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Polar Capital Holdings sold 541,379 Blueprint Medicines shares in Q2 2025, an estimated $47.9M.
Polar Capital Holdings first reported a position in Blueprint Medicines in Q3 2021 and held it in 10 quarters.
Polar Capital Holdings's Blueprint Medicines position peaked at $94.3M in Q2 2024.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Polar Capital Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.